The ubiquitin-proteasome pathway is dysregulated in myeloma cells in the bone microenvironment in vivo

The ubiquitin-proteasome pathway is dysregulated in myeloma cells in the bone microenvironment in vivo

Detalles Bibliográficos
Main Authors:	Edwards, C, Fowler, J, Caldwell, R, Bates, A, Edwards, JR, Zhang, J, Foehr, D, Parker, R, Roberts, A, Mundy, G
Formato:	Conference item
Publicado:	2007

Títulos similares

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
por: Edwards, C, et al.
Publicado: (2009)

Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
por: Edwards, C, et al.
Publicado: (2007)

The importance of the bone marrow microenvironment in multiple myeloma; Differential responses to lithium in vivo
por: Edwards, C, et al.
Publicado: (2006)

Decreased bone marrow-derived adiponectin contributes to myeloma pathogenesis in vivo
por: Fowler, J, et al.
Publicado: (2010)

Targeting Wnt signaling in myeloma in vivo; Differential effects on tumor burden and myeloma bone disease
por: Edwards, C, et al.
Publicado: (2007)

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
por: Edwards, C, et al.
Publicado: (2008)

Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
por: Fowler, J, et al.
Publicado: (2012)

Lithium inhibits the development of myeloma bone disease in vivo.
por: Edwards, C, et al.
Publicado: (2006)

Increasing adiponectin via an apolipoprotein peptide mimetic, L-4F, increases bone formation in normal mice and prevents myeloma bone disease in vivo
por: Fowler, J, et al.
Publicado: (2011)

A murine model of myeloma that allows genetic manipulation of the host microenvironment.
por: Fowler, J, et al.
Publicado: (2009)

Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases
por: Qiuyang Zheng, et al.
Publicado: (2016-12-01)

The Bone Marrow Microenvironment in Multiple Myeloma
por: Edwards, C
Publicado: (2010)

Myeloma cells decrease EphB4 expression in osteoblasts; A novel mechanism for regulation of bone formation in multiple myeloma
por: Bates, A, et al.
Publicado: (2007)

Myeloma cells decrease EphB4 expression in osteoblasts: A novel mechanism for regulation of bone formation in multiple myeloma
por: Bates, A, et al.
Publicado: (2007)

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
por: Gámez, B, et al.
Publicado: (2021)

Host-derived MMP-7 decreases myeloma progression in vivo: An unexpected role for MMP-7 and osteopontin in myeloma pathogenesis
por: Lwin, S, et al.
Publicado: (2011)

Host Bone Marrow-Derived Stromal Cells Promote Myeloma Initiation and Development of Osteolysis
por: Fowler, J, et al.
Publicado: (2008)

Osteoclasts in Myeloma Are Derived from Gr-1(+)CD11b(+) Myeloid Immune Suppressor Cells of the Bone Marrow Niche in Vivo
por: Zhuang, J, et al.
Publicado: (2008)

The pathogenesis of the bone disease of multiple myeloma.
por: Edwards, C, et al.
Publicado: (2008)

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
por: Beatriz Gámez, et al.
Publicado: (2022-01-01)

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.
por: Fowler, J, et al.
Publicado: (2011)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
por: Lwin, S, et al.
Publicado: (2017)

Involvement of the ubiquitin-proteasome system in the regulation of the tumor microenvironment and progression
por: Yulan Huang, et al.
Publicado: (2025-03-01)

Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche
por: Zhuang, J, et al.
Publicado: (2007)

#38. Cholesterol increases bone marrow tumour burden in myeloma in vivo and promotes myeloma cell viability and bortezomib resistance ex vivo
por: B. Gámez, et al.
Publicado: (2024-04-01)

Tumor-host cell interactions in the bone disease of myeloma.
por: Fowler, J, et al.
Publicado: (2011)

Diet-induced obesity promotes a myeloma-like condition in vivo.
por: Lwin, S, et al.
Publicado: (2014)

EphB4 Expression in Osteoblasts is Regulated by Myeloma Cells and the Wnt Signaling Pathway.
por: Bates, A, et al.
Publicado: (2008)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
por: Locklin, R, et al.
Publicado: (2007)

The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy
por: Yongmei Wang, et al.
Publicado: (2024-09-01)

The ubiquitin-proteasome pathway in cancer.
por: Spataro, V, et al.
Publicado: (1998)

Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment
por: Olechnowicz, SWZ, et al.
Publicado: (2019)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Jonas Schwestermann, et al.
Publicado: (2022-05-01)

The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease.
por: Julia Dotterweich, et al.
Publicado: (2016-01-01)

Metabolism in the tumour-bone microenvironment
por: Whitburn, J, et al.
Publicado: (2021)

Enzymatic Blockade of the Ubiquitin-Proteasome Pathway
por: Ernst, Robert, et al.
Publicado: (2011)

Ubiquitin Proteasome System in Stress and Disease
por: Dmitry Karpov, et al.
Publicado: (2012-01-01)

The Ubiquitin-Proteasome Pathway in Huntington's Disease
por: Siddhartha Mitra, et al.
Publicado: (2008-01-01)

Ubiquitin-proteasome system in diabetic retinopathy
por: Zane Svikle, et al.
Publicado: (2022-07-01)

The Ubiquitin–Proteasome System in Immune Cells
por: Gonca Çetin, et al.
Publicado: (2021-01-01)